dc.creator | Sakkas L.I., Bogdanos D.P. | en |
dc.date.accessioned | 2023-01-31T09:53:16Z | |
dc.date.available | 2023-01-31T09:53:16Z | |
dc.date.issued | 2016 | |
dc.identifier | 10.1016/j.autrev.2015.10.005 | |
dc.identifier.issn | 15689972 | |
dc.identifier.uri | http://hdl.handle.net/11615/78723 | |
dc.description.abstract | Systemic sclerosis (SSc) is characterized by widespread fibrosis, microangiopathy (vasospasms and stenosis), and formation of autoantibodies. T cell activation has been shown to contribute to fibrosis and microvasculopathy in SSc. However, recent evidence suggests that B cells are also likely to contribute in the pathogenesis of the disease. B cells are hyperactivated in SSc, as indicated by the overexpression of the stimulatory CD19 receptor and impairment of the inhibitory CD22 receptor. They lead to the production of many autoantibodies, some of which induce collagen production and vasoconstriction. They promote fibroblast collagen production through cell contact. Furthermore, B cells can function as antigen-presenting cells to T cells and induce dendritic cell maturation that promotes profibrotic Th2 response. Lately, interleukin (IL)-10-producing B regulatory cells, which induce generation of T regulatory cells and can ameliorate autoimmune diseases, were found to be reduced in SSc, favoring autoaggression of B cells in this disease. Finally, B cell depletion with rituximab improves or stabilizes skin fibrosis and lung function. These finding suggest that new therapeutic strategies targeting B cell function(s) can be developed for SSc. © 2015 Elsevier B.V. | en |
dc.language.iso | en | en |
dc.source | Autoimmunity Reviews | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84954324103&doi=10.1016%2fj.autrev.2015.10.005&partnerID=40&md5=bde78fdcd539f80a8d926e1bc3d60bc8 | |
dc.subject | angiotensin 1 receptor | en |
dc.subject | autoantibody | en |
dc.subject | B cell activating factor | en |
dc.subject | B lymphocyte receptor | en |
dc.subject | bleomycin | en |
dc.subject | bone morphogenetic protein | en |
dc.subject | CD19 antigen | en |
dc.subject | CD22 antigen | en |
dc.subject | collagen | en |
dc.subject | endothelin 1 | en |
dc.subject | endothelin 1 type a receptor | en |
dc.subject | interleukin 10 | en |
dc.subject | interleukin 6 | en |
dc.subject | interleukin 8 | en |
dc.subject | interstitial collagenase | en |
dc.subject | monocyte chemotactic protein 1 | en |
dc.subject | reactive oxygen metabolite | en |
dc.subject | rituximab | en |
dc.subject | stromelysin | en |
dc.subject | toll like receptor 9 | en |
dc.subject | transforming growth factor beta | en |
dc.subject | unclassified drug | en |
dc.subject | vascular cell adhesion molecule 1 | en |
dc.subject | autoantibody | en |
dc.subject | allogeneic hematopoietic stem cell transplantation | en |
dc.subject | antigen presenting cell | en |
dc.subject | autoimmune disease | en |
dc.subject | B lymphocyte | en |
dc.subject | B lymphocyte activation | en |
dc.subject | cell contact | en |
dc.subject | cell maturation | en |
dc.subject | cell therapy | en |
dc.subject | chronic graft versus host disease | en |
dc.subject | cytokine production | en |
dc.subject | dendritic cell | en |
dc.subject | endothelium cell | en |
dc.subject | fibroblast | en |
dc.subject | gene overexpression | en |
dc.subject | humoral immune deficiency | en |
dc.subject | lung function | en |
dc.subject | mouse | en |
dc.subject | nonhuman | en |
dc.subject | pathogenesis | en |
dc.subject | preeclampsia | en |
dc.subject | regulatory T lymphocyte | en |
dc.subject | Review | en |
dc.subject | signal transduction | en |
dc.subject | skin fibrosis | en |
dc.subject | systemic sclerosis | en |
dc.subject | Th2 cell | en |
dc.subject | vasoconstriction | en |
dc.subject | animal | en |
dc.subject | B lymphocyte | en |
dc.subject | human | en |
dc.subject | immunology | en |
dc.subject | lymphocyte activation | en |
dc.subject | systemic sclerosis | en |
dc.subject | Animals | en |
dc.subject | Antigen-Presenting Cells | en |
dc.subject | Autoantibodies | en |
dc.subject | B-Lymphocytes | en |
dc.subject | Humans | en |
dc.subject | Lymphocyte Activation | en |
dc.subject | Scleroderma, Systemic | en |
dc.subject | Th2 Cells | en |
dc.subject | Elsevier | en |
dc.title | Systemic sclerosis: New evidence re-enforces the role of B cells | en |
dc.type | other | en |